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Abstract
The gentamicin minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae isolates 
were determined. Seventy-three percent of isolates demonstrated an MIC range of 8 to 16 μg/mL, 
and 27% demonstrated an MIC of 4 μg/mL or less. Significant associations between gentamicin 
MIC and resistance or reduced susceptibility to other antimicrobials were found.
Gonorrhea is the second most commonly reported notifiable disease in the United States, 
with over 395,000 reported cases in 2015.1 Left untreated, gonorrhea can cause adverse 
reproductive health outcomes in women, such as pelvic inflammatory disease and infertility.
2
 Prevention of gonorrhea sequelae depends on timely diagnosis and effective antimicrobial 
treatment.2 The bacterium that causes gonorrhea, Neisseria gonorrhoeae, has developed 
resistance to multiple classes of antimicrobials over the past 60 years3; formerly 
recommended therapies penicillin, tetracycline, and fluoroquinolones are no longer 
recommended for treatment.4 The Centers for Disease Control and Prevention currently 
recommends dual therapy of ceftriaxone and azithromycin to treat gonorrhea. However, with 
cephalosporin allergy in some patients and concerning reports of cephalosporin-resistant 
gonorrhea,4,5 alternative noncephalosporin therapies are needed.
Gentamicin is an aminoglycoside antimicrobial that has been used in many developing 
countries to treat gonorrhea due to its low cost and high efficacy.6 In a recent US study, 
combination therapy of gentamicin and azithromycin was shown to micro-biologically cure 
100% of uncomplicated urogenital gonorrhea cases.7 Although these findings indicate that 
gentamicin may be an efficacious treatment for uncomplicated gonorrhea, little is known 
about gentamicin susceptibility among strains in the United States.
METHODS
We used data collected through the Gonococcal Isolate Surveillance Project (GISP) to 
investigate N. gonorrhoeae gentamicin minimum inhibitory concentration (MIC) 
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distribution. Established in 1986, GISP allows the Centers for Disease Control and 
Prevention to conduct sentinel surveillance of N. gonorrhoeae antimicrobial susceptibility to 
inform treatment recommendations. Monthly, 25 to 30 participating STD clinics collect 
urethral N. gonorrhoeae isolates from the first 25 men presenting with gonococcal urethritis. 
Associated clinical and demographic data, including age, gender, gender of sex partners, and 
treatment are abstracted from the medical records by the clinic staff. Isolates undergo 
susceptibility testing by agar dilution for azithromycin, cefixime, ceftriaxone, ciprofloxacin, 
penicillin, tetracycline, and gentamicin at regional laboratories. Gonococcal Isolate 
Surveillance Project began gentamicin susceptibility testing in 2015. Susceptibility results 
are generated as MICs. Clinical and Laboratory Standards Institute interpretive criteria for 
gentamicin have not been established. However, criteria based on previous MIC comparisons 
and clinical cure data have characterized MICs of 4 μg/mL or less as susceptible, 8 to 16 
μg/mL as intermediate susceptible, and 32 μg/mL or higher as resistant.8–10 Bivariate 
analyses of gonococcal infection and isolate characteristics were conducted using χ2 
statistics.
RESULTS
During 2015 and 2016, 10,403 urethral N. gonorrhoeae isolates were tested for gentamicin 
susceptibility. Gentamicin MICs ranged from 1 to 16 μg/mL. Of 10,403 isolates, 7603 (73%) 
demonstrated intermediate susceptibility (MIC range, 8–16 μg/mL), 2800 (27%) 
demonstrated full susceptibility (MIC, ≤4 μg/mL), and none demonstrated resistance (MIC, 
≥32 μg/mL) (Fig. 1). The MIC50 and MIC90 were 8 μg/mL. The percentage of intermediate 
susceptible isolates increased from 68% in 2015 to 78% in 2016 (P < 0.0001).
Isolates obtained from clinics in the west census region demonstrated the highest prevalence 
of intermediate susceptibility (84%), followed by the south (74%), the northeast (68%), and 
the midwest (61%) (P < 0.0001) (Table 1). Isolates from patients identifying as gay, 
bisexual, and other men who have sex with men (gender of sex partner data are collected in 
accordance with local clinic practice and can include chart notation from previous visits, 
patient self-report of sexual orientation, or both, or sex of sex partner [from past 3, 6, or 12 
months]) demonstrated a higher prevalence of intermediate susceptibility (81%) than isolates 
from men who have sex only with women (68%) (P < 0.0001). Eighty percent of the isolates 
from patients known to be living with diagnosed HIV demonstrated intermediate 
susceptibility to gentamicin compared with 72% of isolates from patients not known to be 
living with diagnosed HIV (P < 0.0001).
Twenty-eight isolates demonstrated elevated MIC (MIC ≥0.125 μg/mL) to ceftriaxone; 25 
(89%) of these isolates also demonstrated intermediate susceptibility to gentamicin (Table 
2). Of the 323 isolates demonstrating elevated MIC (MIC ≥2.0 μg/mL) to azithromycin, 305 
(94%) demonstrated intermediate susceptibility to gentamicin (P < 0.0001). Intermediate 
gentamicin susceptibility was associated with resistance to penicillin, tetracycline, 
ciprofloxacin, and cefixime, and azithromycin elevated MIC (P < 0.05). Eighty-six (<1%) 
sampled gonococcal urethritis infections were treated primarily with gentamicin; 72 (84%) 
corresponding isolates demonstrated intermediate susceptibility to gentamicin. Of the 86 
sampled infections treated with gentamicin, 82 (95%) were treated in combination with 
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azithromycin, 3 (3%) were treated in combination with doxycycline, and 1 (1%) was treated 
only with gentamicin.
DISCUSSION
This report provides findings from the largest surveillance sample of N. gonorrhoeae isolates 
tested for gentamicin susceptibility to date. Without the existence of gentamicin Clinical and 
Laboratory Standards Institute clinical breakpoint criteria, the clinical interpretation of our 
findings is limited. These findings may serve as a measure of the MIC distribution when 
such interpretative criteria become established for gentamicin.
Previous international studies have assessed gonococcal gentamicin susceptibility by agar 
dilution. A 2009 survey of gentamicin susceptibility on 1366 gonococcal isolates from 17 
European Union countries found that 16% of isolates demonstrated an MIC of 4 mg/L 
(equivalent to μg/mL), and 79% of isolates demonstrated an MIC of 8 mg/L.9 A 2007 survey 
of 100 isolates from Malawi showed a stable agar dilution MIC range of 1 to 4 μg/mL in the 
context of 14 years of routine use of dual treatment with gentamicin and doxycycline for 
urethritis.8,10 Our findings indicate the continued susceptibility of N. gonorrhoeae to 
gentamicin, but diverge from previous reports in demonstrating a wider and higher MIC 
range, with 71% of the isolates demonstrating an MIC of 8 μg/mL and 2% of the isolates 
demonstrating an MIC of 16 μg/mL. The increase in the proportion of intermediate 
susceptible isolates between 2015 and 2016 points to the possibility that susceptibility to 
gentamicin might be decreasing; continued surveillance of gentamicin susceptibility is 
needed.
This report is subject to limitations. Gonococcal Isolate Surveillance Project only collects 
male urethral N. gonorrhoeae isolates. Although some studies suggest that gonococcal 
antimicrobial susceptibility surveillance based on urethral isolates adequately reflects, at the 
population level, the susceptibilities of circulating N. gonorrhoeae strains, other studies 
suggest that disparities in susceptibility exist by anatomic site of infection and sex.11,12 It 
may thus be prudent for future gentamicin susceptibility studies to include rectal, 
pharyngeal, and cervical isolates. Moreover, GISP participants do not comprise a nationally 
representative sample of all persons with gonorrhea; only men presenting at participating 
STD clinics with diagnosed urethral gonorrhea are included. Despite lacking national 
representation, GISP does enable monitoring of antimicrobial susceptibility trends across US 
geographic areas.2
Because gonorrhea is not routinely treated with gentamicin in the United States, this study 
could not assess the correlation between gentamicin treatment patterns and MIC. 
Furthermore, GISP does not collect clinical outcome information; this report thus could not 
assess the relationship between gentamicin MIC and treatment outcome. Further studies are 
needed to assess the relationship between treatment practices and outcome and gentamicin 
MIC.
The high incidence of gonorrhea coupled with increasing antimicrobial resistance warrants 
the consideration of alternative therapies. In combination with other therapies, gentamicin 
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can be a low-cost and efficacious alternative therapy; continued surveillance of gentamicin 
susceptibility and further investigation of gentamicin as therapy for gonorrhea is warranted.
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Figure 1. 
Susceptibility of N. gonorrhoeae isolates to gentamicin*—Gonococcal Isolate Surveillance 
Project, United States, 2015–2016.
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TABLE 1
Differences in N. gonorrhoeae Gentamicin Susceptibility Patterns by US Census Region, Sex of Sex Partner, 
and HIV Status—Gonococcal Isolate Surveillance Project, United States, 2015–2016*
Susceptible, N (%) Intermediate Susceptible, N (%) Total
Total 2800 (26.9%) 7603 (73.1%) 10,403
Region†
 West 651 (16.4%) 3311 (83.6%) 3962
 Midwest 1145 (40.0%) 1751 (60.5%) 2896
 South 592 (26.0%) 1686 (74.0%) 2278
 Northeast 412 (32.5%) 855 (67.5%) 1267
Gender of sex partner†
 MSW 2023 (31.6%) 4376 (68.4%) 6399
 MSM‡ 752 (19.2%) 3166 (80.8%) 3918
 Unknown 25 (29.1%) 61 (70.9%) 86
HIV status†
 Not known to be living with diagnosed HIV 2435 (28.1%) 6236 (71.9%) 8671
 Known to be living with diagnosed HIV 195 (19.6%) 801 (80.4%) 996
Unknown 170 (23.1%) 566 (76.9%) 736
*Clinical sites include: Albuquerque, NM; Atlanta, GA; Birmingham, AL; Boston, MA; Buffalo, NY; Chicago, IL; Cleveland, OH; Columbus, OH; 
Dallas, TX; Greensboro, NC; Honolulu, HI; Indianapolis, IN; Kansas City, MO; Los Angeles, CA; Las Vegas, NV; Minneapolis, MN; New 
Orleans, LA; New York, NY; Orange County, CA; Philadelphia, PA; Phoenix, AZ; Pontiac, MI; Portland, OR; San Diego, CA; Seattle, WA; San 
Francisco, CA; Tripler Army Medical Center, HI.
†P < 0.0001.
‡
Includes men who have sex with men and women.
MSM indicates men who have sex with men; MSW, men who have sex with women only.
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TABLE 2
Associations Between Susceptibility of N. gonorrhoeae Isolates to Gentamicin and Resistance to Penicillin, 
Tetracycline, or Ciprofloxacin, or Elevated MICs to Ceftriaxone, Cefixime, or Azithromycin*—GISP, United 
States, 2015–2016
Susceptible to Gentamicin Intermediate Susceptible to Gentamicin
Total 2800 (26.9%) 7603 (73.1%)
Penicillin† Susceptible 2433 (28.1%) 6227 (71.9%)
Resistant 367 (21.1%) 1376 (78.9%)
Tetracycline† Susceptible 2313 (29.0%) 5655 (71.0%)
Resistant 487 (20.0%) 1948 (80.0%)
Ciprofloxacin† Susceptible 2259 (28.8%) 5586 (71.2%)
Resistant 541 (21.1%) 2017 (78.9%)
Ceftriaxone Susceptible 2797 (27.0%) 7578 (73.0%)
Elevated MIC 3 (10.7%) 25 (89.3%)
Cefixime‡ Susceptible 2796 (27.0%) 7565 (73.0%)
Elevated MIC 4 (9.5%) 38 (90.5%)
Azithromycin† Susceptible 2782 (27.6%) 7298 (72.4%)
Elevated MIC 18 (5.6%) 305 (94.4%)
*
Penicillin resistance = MIC ≥2.0 μg/mL, tetracycline resistance = MIC ≥2.0 μg/mL, ciprofloxacin resistance = MIC ≥1.0 μg/mL, ceftriaxone 
elevated MIC = MIC ≥0.125 μg/mL, cefixime elevated MIC = MIC ≥0.25 μg/mL, azithromycin elevated MIC = MIC ≥2.0 μg/mL.
†P < 0.0001.
‡P = 0.0109.
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